Hostname: page-component-8448b6f56d-qsmjn Total loading time: 0 Render date: 2024-04-16T19:49:43.577Z Has data issue: false hasContentIssue false

Rapid and economical detection of eight carbapenem-resistance genes in Enterobacteriaceae, Pseudomonas spp, and Acinetobacter spp directly from positive blood cultures using an internally controlled multiplex-PCR assay

Published online by Cambridge University Press:  06 May 2019

Surojit Das
Affiliation:
Department of Microbiology, Tata Medical Center, Kolkata, India
Subhanita Roy
Affiliation:
Department of Microbiology, Tata Medical Center, Kolkata, India
Samadrita Roy
Affiliation:
Department of Microbiology, Tata Medical Center, Kolkata, India
Gaurav Goel
Affiliation:
Department of Microbiology, Tata Medical Center, Kolkata, India
Kamini Walia
Affiliation:
Indian Council of Medical Research, New Delhi, India
Sudipta Mukherjee
Affiliation:
Department of Critical Care, Tata Medical Center, Kolkata, India
Sanjay Bhattacharya*
Affiliation:
Department of Microbiology, Tata Medical Center, Kolkata, India
Mammen Chandy
Affiliation:
Department of Clinical Hematology, Tata Medical Center, Kolkata, India
*
Author for correspondence: Sanjay Bhattacharya, Emails: sanjay.bhattacharya@tmckolkata.com or drsanjay1970@hotmail.com
Rights & Permissions [Opens in a new window]

Abstract

Type
Letter to the Editor
Copyright
© 2019 by The Society for Healthcare Epidemiology of America. All rights reserved. 

To the Editor—The World Health Organization (WHO) has recognized carbapenem-resistant Enterobacteriaceae (CRE), Pseudomonas aeruginosa (CRPsA), and Acinetobacter baumannii (CRAB) as critical pathogens that cause significant morbidity and mortality in patients with bloodstream infections (BSIs), especially in healthcare settings. 1 , Reference Banerjee and Humphries 2 Carbapenem resistance challenges empirical and targeted antibiotic treatment involving β-lactam antibiotics, including carbapenems, and it results in expensive and complicated alternative anti-infective strategies with polymyxin-B, colistin, tigecycline, and fosfomycin.Reference Cortegiani, Russotto and Graziano 3 Despite their high cost (∼US$62 per test), commercially available PCR-based tests have been used to screen clinically important carbapenemases, known as the “Big 5” genes: metallo-β-lactamases (MBLs) (ie, NDM, IMP, and VIM), KPC, and the OXA-48 family. These tests use rectal swab samples with short turnaround times (TATs), which contribute significantly to infection control efforts.Reference Banerjee and Humphries 2 , Reference Findlay, Hopkins, Meunier and Woodford 4 , Reference Codjoe and Donkor 5 Few validated tests are available to meet the acute need in BSI cases.Reference Banerjee and Humphries 2 , Reference Findlay, Hopkins, Meunier and Woodford 4 A rapid, inexpensive, and accessible testing tool for carbapenemase producing-carbapenem resistant organisms (CP-CRO) as pathogens of BSI is of paramount importance for early institution of effective antimicrobial therapy and infection prevention and its control. In the present study, a predesigned multiplex PCR assay was validated that targets the OXA carbapenemases (OXA-23, OXA-24/-143, and the OXA-58 family) commonly harbored by Acinetobacter spp, as well as with the “Big 5” genes, in DNA extracts of gram-negative bacilli positive blood-culture (BC) broths.

In this prospective study, consecutive BC broth samples (n = 415) were collected from patients (n = 278) with laboratory-confirmed BSIs at Tata Medical Center, Kolkata, India, from July 2017 to September 2018. Blood culturing was performed using the BacT/Alert 3D system (bioMérieux, Marcy-l’Étoile, France), and identification and susceptibility testing of BC isolates were performed using the Vitek2 system (bioMérieux). Carbapenem susceptibility results were interpreted following Clinical Laboratory Standard Institute (CLSI) guidelines. 6

DNA was extracted from positive BC broths using the alkali wash and heat lysis method.Reference Millar, Jiru, Moore and Earle 7 Additionally, 20 µL McFarland 3 turbidity standard of A. baumannii ATCC19606 was added to 500 µL BC broth before extraction as an internal extraction control (IEC). Two multiplex PCRs were then performed to detect 8 carbapenemase genes (as described earlier) with a modification: CARBA (KPC, 353 base pairs [bp]; NDM, 603 bp; VIM, 437 bp; IMP, 387 bp; OXA-48 family, 265 bp) and OXA (OXA-23 family, 330 bp; OXA-24/143 family, 271 bp; OXA-58 family, 688 bp; with Acinetobacter-derived AmpC [ADC] as the IEC and PCR control, 1,059 bp).Reference Bogaerts, Rezende de Castro, de Mendonca, Haung, Denis and Glupczynski 8 The PCR amplicons were visualized on 3% prestained agarose gels. Bidirectional sequencing was performed using a 3500 DNA analyzer (Applied Biosystems, Foster City, CA) for confirmation. Analytical specificities of multiplex PCRs were validated using bacterial and fungal reference strains and clinical isolates. For assay standardization, cultured reference strains were suspended in normal saline to a density of 0.5 McFarland turbidity standard (∼1.5 × 108 CFU/mL) using a Densimat (bioMerieux) followed by preparation of 10-fold serial dilutions ranging from 107to 102 CFU/mL. Known negative BC samples (450 µL) incubated for 5 days were spiked with bacterial dilutions (50 µL), and DNA extraction followed by PCR was preformed to check analytical sensitivity.

Statistical performance indicators of the multiplex PCRs were determined using MedCalc (MedCalc Software, Mariakerke, Belgium) using carbapenem susceptibilities of Enterobacteriaceae, Pseudomonas spp, and Acinetobacter spp (EPA) as references. Non-EPA, intrinsically CRO, and uncultivable organisms were considered negative controls. Interrater agreement using Cohen’s κ was used to measure the concordance between culture and multiplex PCRs.

Of 153 CARBA-OXA multiplex PCR–positive samples, 122 had a single target (NDM, 48; OXA-48 family, 66; KPC, 2; VIM, 2; and OXA-23 family, 4) and 31 had double targets (NDM/OXA-48 family, 20; NDM/OXA-58 family, 5; KPC/VIM, 2; NDM/OXA-23 family, 2; NDM/VIM, 1; and OXA-48/OXA-58 family, 1) (Table 1). The analytical specificities of the PCRs were 100% for detecting the 8 carbapenemases; the sensitivities ranged between 500 and 5000 CFU/mL for different carbapenemases using spiked BC samples. Among 415 BC samples, accuracy of the assay was marginally improved (95.9% vs 96.9%) using both the “Big 5” CARBA and extended OXA panels (Supplementary Table 1 online). Discrepant results between the culture method and multiplex-PCRs were observed in 13 samples. The TAT for the detection of carbapenemases was <4 hours using BC positive broth, including DNA extraction (∼50 minutes), PCR amplification (∼120 minutes), and agarose-gel electrophoresis and documentation (∼30 minutes). The cost of consumables and reagents for running the assays was only ∼US$10 per sample.

Table 1. Distribution of Different Carbapenemases in Enterobacteriaceae, Pseudomonas spp, and Acinetobacter spp Isolated From Blood Samples

Note: ND, not detected by polymerase chain reaction assay.

Early and rapid detection of carbapenemases in common gram-negative bacilli is of paramount importance for optimizing antimicrobial therapy, as a tool for antimicrobial stewardship programs, for hospital infection control, and for improving patient outcomes with regard to morbidity, mortality, reducing length of hospitalization, and minimizing the cost of health care. Compared with commercial assays (eg, Carba R GeneXpert from Cepheid, Sunnyvale, CA), the cost of the current assay was significantly less with a convenient TAT (same-day result) using this noncommercial DNA extraction method and end-point multiplex PCR format.Reference Findlay, Hopkins, Meunier and Woodford 4 , Reference Codjoe and Donkor 5 , Reference Tato, Ruiz-Garbajosa and Traczewski 9 In this study, we validated the diagnostic performance of internally controlled multiplex-PCRs targeting 8 carbapenemases in BC-positive samples. In the wake of increased carbapenem-based antimicrobial therapies, multiplex PCR may prove to be a useful tool for detecting carbapenem resistance and thus facilitating early infection control actions in clinical settings. The strengths of the current study include (1) demonstration of the molecular epidemiology of carbapenem resistance genes among a group of oncology patients in eastern India, (2) development of a rapid and cost effect test suitable for implementation in resource constrained settings; (3) application of molecular tests for gram negative bacteremia to optimize antibiotic therapy; (4) identification of potential targets for developing new drugs to treat NDM and OXA positive GNB infections, and (5) use of OXA-23/-24/-58 PCRs, which has been rarely investigated for diagnostic purposes apart from its importance as a marker in CRAB associated with outbreaks (OXA-23).Reference Codjoe and Donkor 5 The implementation of this new, low-cost tool in resource-limited settings may enable better management of gram-negative sepsis.Reference Nordmann and Poirel 10

Author ORCIDs

Sanjay Bhattacharya, 0000-0003-4139-1039

Supplementary material

To view supplementary material for this article, please visit https://doi.org/10.1017/ice.2019.79.

Acknowledgments

We would like to thank the Indian Council of Medical Research for supporting the study.

Financial support

The financial support for this work came from the Indian Council of Medical Research.

Conflicts of interest

All authors report no conflicts of interest relevant to this article.

References

WHO. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. WHO documents. Geneva: World Health Organization; 2017.Google Scholar
Banerjee, R, Humphries, R. Clinical and laboratory considerations for the rapid detection of carbapenem-resistant Enterobacteriaceae . Virulence 2017;8:427439.10.1080/21505594.2016.1185577CrossRefGoogle ScholarPubMed
Cortegiani, A, Russotto, V, Graziano, G, et al. Use of Cepheid Xpert Carba-R1 for rapid detection of carbapenemase-producing bacteria in abdominal septic patients admitted to intensive care unit. PLoS One 2016;11:e0160643.CrossRefGoogle ScholarPubMed
Findlay, J, Hopkins, KL, Meunier, D, Woodford, N. Evaluation of three commercial assays for rapid detection of genes encoding clinically relevant carbapenemases in cultured bacteria. J Antimicrob Chemother 2015;70:13381342.10.1093/jac/dku571CrossRefGoogle ScholarPubMed
Codjoe, FS, Donkor, ES. Carbapenem resistance: a review. Med Sci 2018;6:128.Google Scholar
CLSI. Performance Standards for Antimicrobial Susceptibility Testing, 28th edition, CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.Google Scholar
Millar, BC, Jiru, X, Moore, JE, Earle, JA. A simple and sensitive method to extract bacterial, yeast and fungal DNA from blood culture material. J Microbial Methods 2000;42:139147.CrossRefGoogle ScholarPubMed
Bogaerts, P, Rezende de Castro, R, de Mendonca, R, Haung, TD, Denis, O, Glupczynski, Y. Validation of carbapenemase and extended-spectrum β-lactamase multiplex endpoint PCR assays according to ISO 15189. J Antimicrob Chemother 2013;68:15761582.CrossRefGoogle ScholarPubMed
Tato, M, Ruiz-Garbajosa, P, Traczewski, M, et al. Multisite evaluation of Cepheid Xpert Carba-R assay for detection of carbapenemase-producing organisms in rectal swabs. J Clin Microbiol 2016;54:18141819.CrossRefGoogle ScholarPubMed
Nordmann, P, Poirel, L. The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide. Clin Microbial Infect 2014;20:821830.CrossRefGoogle ScholarPubMed
Figure 0

Table 1. Distribution of Different Carbapenemases in Enterobacteriaceae, Pseudomonas spp, and Acinetobacter spp Isolated From Blood Samples

Supplementary material: File

Das et al. supplementary material

Online Table

Download Das et al. supplementary material(File)
File 12.8 KB